Rigel Pharmaceuticals RIGL Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Rigel Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's return on assets?
- Rigel Pharmaceuticals (RIGL) reported return on assets of 107% in Q1 2026.
- How has Rigel Pharmaceuticals's return on assets changed year-over-year?
- Rigel Pharmaceuticals's return on assets increased by 335.4% year-over-year, from 24.6% to 107%.
- What is the long-term trend for Rigel Pharmaceuticals's return on assets?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's return on assets has grown at a 36.3% compound annual growth rate (CAGR), from -23.1% to 108.3%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.